Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 11Terminated 4Active not recruiting 2Withdrawn 1Unknown 1Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 12Prostatic Neoplasms 11Head and Neck Neoplasms 7Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 6Esophageal Neoplasms 5Rectal Neoplasms 4Mouth Neoplasms 4Laryngeal Neoplasms 4Glioma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Papillomavirus Infections 2Oligodendroglioma 2Myelodysplastic Syndromes 2Lymphatic Metastasis 2Leukemia, Myeloid, Acute 2Hypopharyngeal Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Astrocytoma 2Anus Neoplasms 2Virus Diseases 1Vaginal Neoplasms 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × Radiotherapy, Intensity-Modulated × Clear all
NCT03251027 2026-01-27

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Thomas Jefferson University

Phase NA Active not recruiting
100 enrolled
CNS

Glioblastoma

NCT02179086 2026-01-14

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2 Active not recruiting
606 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡